OKL-1111, A modified cyclodextrin as a potential universal reversal ...
2023年7月1日 · OKL-1111 was discovered as a lead candidate from a class of cyclodextrins that can reverse the anticoagulant action of DOACs in the in vitro thrombin generation assay. …
OKL-1111，一种改性环糊精，作为抗凝剂的潜在通用逆转 …
在这项研究中，我们表征了一种先导化合物 okl-1111，并证明了其作为通用逆转剂的潜在用途。 目标. 评估 okl-1111 的体外和体内抗凝逆转特性。 方法. 在凝血酶生成测定中研究了 okl-1111 在 …
OKL-1111 (OKL-1111) - 在研适应症：出血性卒中，颅内出血_专 …
OKL-1111 has a universal mode of action by binding to a downstream clotting factor and a unique product profile, enabling administration within 10 minutes of a diagnosing CT scan. In addition, …
First in-Human Study with Okl-1111, a Novel Small ... - ScienceDirect
2024年11月5日 · OKL-1111 reversed the action of a wide variety of anticoagulants (dabigatran, apixaban, rivaroxaban, edoxaban, warfarin, enoxaparin and fondaparinux) as well as platelet …
Sanquin ResearchThrombosis Research（IF=10）:OKL-1111，一种 …
2023年5月8日 · okl-1111是一种具有潜在成为通用逆转剂的环糊精类化合物。研究结果表明，okl-1111可以逆转各种抗凝剂和血小板抑制剂的作用，包括doacs、维生素k拮抗剂华法林、低分 …
Reversal of anticoagulants by gamma-cyclodextrin derivative
2023年6月14日 · OKL-1111 in a concentration-dependent manner, reversed the in vitro anticoagulant effects of dabigatran, rivaroxaban, apixaban and edoxaban in the thrombin …
2023年2月13日 · Results: OKL-1111 concentration-dependently reversed the in vitro anticoagulant effects of dabigatran, rivarox- aban, apixaban and edoxaban in the thrombin …
Alveron Pharma completes successful first-in-human trial of OKL …
2023年10月2日 · Alveron Pharma announces that it has completed a Phase 1 clinical study for OKL-1111, a new drug for the rapid treatment of Intracranial Haemorrhage (ICH) and other life …
OKL-1111, A modified cyclodextrin as a potential universal reversal ...
2025年2月13日 · OKL-1111, A modified cyclodextrin as a potential universal reversal agent for anticoagulants OKL-1111，一种作为抗凝剂潜在通用逆转剂的改性环糊精 相关领域
OKL-1111 by Alveron Pharma for Brain Hemorrhage: Likelihood of …
OKL-1111 is under development for the treatment of intracranial haemorrhage (ICH). It is administered through parenteral route as a solution. The drug candidate is a procoagulant …